Dujic, T.; Cvijic, S.; Elezovic, A.; Bego, T.; Imamovic Kadric, S.; Malenica, M.; Elezovic, A.; Pearson, E.R.; Kulo, A.
Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. J. Pers. Med. 2021, 11, 367.
https://doi.org/10.3390/jpm11050367
AMA Style
Dujic T, Cvijic S, Elezovic A, Bego T, Imamovic Kadric S, Malenica M, Elezovic A, Pearson ER, Kulo A.
Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. Journal of Personalized Medicine. 2021; 11(5):367.
https://doi.org/10.3390/jpm11050367
Chicago/Turabian Style
Dujic, Tanja, Sandra Cvijic, Amar Elezovic, Tamer Bego, Selma Imamovic Kadric, Maja Malenica, Alisa Elezovic, Ewan R. Pearson, and Aida Kulo.
2021. "Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype" Journal of Personalized Medicine 11, no. 5: 367.
https://doi.org/10.3390/jpm11050367
APA Style
Dujic, T., Cvijic, S., Elezovic, A., Bego, T., Imamovic Kadric, S., Malenica, M., Elezovic, A., Pearson, E. R., & Kulo, A.
(2021). Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. Journal of Personalized Medicine, 11(5), 367.
https://doi.org/10.3390/jpm11050367